1. Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy
- Author
-
R. Levitin, Maha S. Jawad, Nayana Dekhne, Pamela Benitez, Thomas J. Quinn, G.S. Gustafson, Sayee Kiran, Amita Desai, Muayad F. Almahariq, Peter Y. Chen, and Joshua T. Dilworth
- Subjects
Oncology ,medicine.medical_specialty ,Sentinel lymph node ,Breast Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Surgical oncology ,Internal medicine ,Medicine ,Humans ,Prospective Studies ,Lymph node ,business.industry ,Sentinel Lymph Node Biopsy ,Axillary Lymph Node Dissection ,Cancer ,medicine.disease ,Neoadjuvant Therapy ,Axilla ,Dissection ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Lymphatic Metastasis ,Lymph Node Excision ,030211 gastroenterology & hepatology ,Surgery ,business - Abstract
The appropriateness of substituting sentinel lymph node dissection (SLND) and regional nodal irradiation (RNI) for axillary lymph node dissection (ALND) in patients with residual lymph node (LN) disease following neoadjuvant chemotherapy (NAC) is unknown. We used the National Cancer Database (NCDB) to compare survival following SLND and ALND in breast cancer patients with residual LN disease. We analyzed NCDB patients, treated between 2006 and 2014, with cT1–3, cN1, cM0 breast cancer and residual disease in 1–3 axillary LNs (ypN1) following NAC. Patients were grouped into those who received SLND (defined as removal of ≤ 4 LNs) and RNI, or ALND and RNI. Patients were matched for all patient, tumor, and treatment characteristics. We identified 1313 eligible patients in the ALND group and 304 patients in the SLND group. For the matched cohorts, SLND was associated with significantly lower survival in both univariate and doubly robust multivariable analyses (MVA) (HR 1.7, 95% CI 1.3–2.2, P
- Published
- 2020